The interaction of oncogene and tumour suppressor gene defects with cytotoxic drugs: its role in the improvement of selective toxicity and the development of new drugs in clinical oncology.
Petty
R D
RD
Ninewells Hospital and Medical School, Dundee, UK.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016147:Genes, Tumor Suppressor / Q000187:drug effects / Q000235:genetics*; D016259:Genes, myc / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D009857:Oncogenes / Q000187:drug effects / Q000235:genetics*
D000970:Antineoplastic Agents